Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investor euphoria on the company’s vaccine candidate may not be warranted

Why Moderna Could be a Good Short

President Donald Trump's administration announced Monday that former Moderna Inc.

Moncef Slaoui To Divest Moderna Stake As He Joins White House Vaccine Accelerator

Moderna is selling $1.3 billion in stock to help fund its promising new coronavirus vaccine. The biotech firm announced plans to sell 17.6 million shares priced at $76 apiece in a public offering that’s expected to close around Thursday.

Moderna to fund coronavirus vaccine with $1.3 billion stock sale

Moderna Inc. (NASDAQ: MRNA) announced Monday it is planning to raise more than $1.3 billion in a secondary public offering.

Moderna To Raise $1.3B In A Public Offering As Coronavirus Vaccine Trials See Progress

Shares of the COVID-19 vaccine drugmaker are up 339% this year.

Moderna Plans to Raise $1.25 Billion in a Secondary Offering

Newly appointed co-chair of the White House coronavirus vaccine project Moncef Slaoui plans to sell approximately $12.4 million worth of stock options in Moderna over the next 24 hours.

White House coronavirus vaccine adviser Moncef Slaoui to divest $12.4 million of Moderna holdings

Moderna, Inc. (MRNA) SARS-CoV-2 Vaccine (mRNA-1273) Interim Phase 1 Data Conference (Transcript)

The "Mad Money" host explained why investors should shape their portfolio to account for more positive and negative information on the coronavirus fight.

Jim Cramer advises investors not to get too optimistic over Moderna vaccine progress

Moderna said it also expects to grant the underwriters a 30-day option to buy up to an additional $187.5 million in common stock shares in connection with the public offering.

Moderna plans to issue $1.25 billion in fresh equity following 20% stock jump

Moderna Inc's  experimental COVID-19 vaccine, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, according to very early data released by the biotech company on Monday.

Coronavirus vaccine from Moderna appears safe, shows promise in data from eight people

On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.

Here's Why Moderna (MRNA) Stock is Jumping Today

Moderna Inc (NASDAQ: MRNA) shares were trading at new highs Monday following the release of positive interim Phase 1 immunogenicity and safety data for its mRNA-1273 coronavirus vaccine candidate.

Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine

After announcing positive results of a study of its potential COVID-19 vaccine and seeing shares jump 20% to record highs Monday, Moderna Inc.

Moderna plans to sell more than $1 billion in fresh stock after COVID-19 vaccine study success

A vaccine trial in the United States is showing promising early data, after the vaccine reportedly produced protective antibodies in a small group of healthy volunteers.

US vaccine trial shows promising early results, biotech firm says

Massachusetts-based Moderna’s share price — and the stock market as a whole — was lifted today by the company’s encouraging report about a coronavirus vaccine trial that got its start at Seattle’s Kaiser Permanente Washington Health Research Institute.

Positive news about Seattle-tested coronavirus vaccine sends stock market sharply higher

The Phase I trail showed encouraging results, but that’s still a long way from a working vaccine that everyone can take.
Biotech company Moderna reported positive Phase 1 COVID-19 vaccine trial results this morning, boosting its stock shares by 25% and drumming up a media cyclone of excitement.

Moderna’s encouraging vaccine trial: What we know and why the biggest hurdles are still ahead

AstraZeneca

Pfizer

With about eight coronavirus vaccine candidates in clinical trials and 110 more in clinical testing, the race to a commercial product is intensifying.

These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

So far, so good with the phase 1 clinical study of Moderna's promising COVID-19 vaccine.

Moderna Reports Positive Results From Early Stage Study of Coronavirus Vaccine

Investors are excited about promising early data from a study of the biotech's novel coronavirus vaccine.

Why Moderna Stock Is Soaring Today

This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.

Moderna (MRNA) COVID-19 Vaccine Looks Promising

Moderna Inc. (NASDAQ: MRNA) made a big step towards a COVID-19 vaccine early on Monday, and investors (and the stock market in general) responded very positively.

Moderna Is One Big Step Closer to a COVID-19 Vaccine

Shares of Moderna, Inc. (NASDAQ: MRNA) soared more than 30% Monday morning after the company announced encouraging interim clinical data of its vaccine candidate against the coronavirus plaguing the world.

Moderna CEO: ‘Could not be happier’ with coronavirus vaccine data

U.S. stock-index futures added to gains Monday morning, with the market for risk assets gathering additional momentum from a report of success in a vaccine for the COVID=19 pandemic.

Dow futures surge 600 points, adding to Monday gains as Moderna says it sees some success with coronavirus vaccine candidate

U.S. stock benchmarks surged at Monday's open after a report of early success in a vaccine for the COVID=19 pandemic helped to stir optimism on Wall Street.

Dow surges nearly 700 points at Monday's open amid hopeful report on Moderna's experimental coronavirus vaccine

Moderna reported positive results from a Phase 1 study of its coronavirus vaccine on Monday, prompting MRNA stock to catapult higher. Vir Biotechnology is now advanced two Covid-19 drugs.

News for Moderna Stock (MRNA)